• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by IO Biotech Inc.

    4/7/25 4:07:31 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email
    S-8 1 d849886ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on April 7, 2025

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IO BIOTECH, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   87-0909276

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Ole Maaløes Vej 3

    DK-2200 Copenhagen N

    Denmark

    (Address of principal executive offices)

    IO BIOTECH, INC. 2021 EQUITY AND INCENTIVE PLAN

    (Full title of the plan)

    Corporation Trust Company

    Corporation Trust Center

    1209 N Orange Street

    Wilmington, DE 19801

    (800) 677-3394

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement is being filed by IO Biotech, Inc. (the “Registrant”) for the purpose of registering an additional 2,635,236 shares of the Registrant’s Common Stock, par value $0.001 per share (the “Common Stock”), that were reserved for issuance under the IO Biotech, Inc. 2021 Equity and Incentive Plan. This Registration Statement on Form S-8 hereby incorporates by reference the contents of the Registrant’s prior Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on March 11, 2024 (SEC File No.  333-277826), February 6, 2023 (SEC File. No.  333-269597), and February 8, 2022 (SEC File No. 333-262587) (collectively, the “Prior Registration Statements”). This Registration Statement relates to securities of the same class as those to which the prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General E of Form S-8, the contents of the Prior Registration Statements, are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). Documents containing the information required by Part I of the Registration Statement will be sent or given to plan participants as specified by Rule 428(b)(1) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed with the Commission by the Registrant are incorporated in this Registration Statement by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):

     

      (1)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 31, 2025;

     

      (2)

    The description of the Common Stock included in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on November 2, 2021, including any subsequent amendments or reports filed to update such description.

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).

    Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits

     

    Exhibit
    Number

      

    Description

    4.1    Amended and Restated Certificate of Incorporation of IO Biotech, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form 10-Q (Registration No. 001-41008), filed with the Commission on August 11, 2023).
    4.2    Amended and Restated Bylaws of IO Biotech, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed (Registration No. 001-41008), filed with the Commission on December 16, 2024).
    4.3    IO Biotech, Inc. 2021 Equity and Incentive Plan (incorporated by reference to Exhibit 4.3 to our Registration Statement on Form S-8 (Registration No. 333-269597), filed with the Commission on February 6, 2023).
    5.1*    Opinion of Sidley Austin LLP with respect to the validity of the securities being registered hereby.
    23.1*    Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm.
    23.2*    Consent of Sidley Austin LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on the signature page of this Registration Statement).
    107*    Filing Fee Table

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Copenhagen, Denmark, on the 7th day of April, 2025.

     

    IO Biotech, Inc.
    By:  

    /s/ Mai-Britt Zocca

      Mai-Britt Zocca, Ph.D.
      Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    Each of the undersigned officers and directors of IO Biotech, Inc. does hereby severally constitute and appoint Mai-Britt Zocca and Amy Sullivan, and each of them acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE    TITLE    DATE

    /s/ Mai-Britt Zocca

       Chief Executive Officer and Director    April 7, 2025
    Mai-Britt Zocca, Ph.D.    (Principal Executive Officer)   

    /s/ Amy Sullivan

       Chief Financial Officer    April 7, 2025
    Amy Sullivan, M.B.A.    (Principal Financial Officer)   

    /s/ Brian Burkavage

       Chief Accounting Officer & Vice President of Finance    April 7, 2025
    Brian Burkavage    (Principal Accounting Officer)   

    /s/ Peter Hirth

       Chairman of the Board    April 7, 2025
    Peter Hirth, Ph.D.      

    /s/ Helen Collins

       Director    April 7, 2025
    Helen Collins, M.D.      

    /s/ Christian Elling

       Director    April 7, 2025
    Christian Elling, Ph.D.      

    /s/ Kathleen Sereda Glaub

       Director    April 7, 2025
    Kathleen Sereda Glaub, M.B.A.      

    /s/ Heidi Hunter

       Director    April 7, 2025
    Heidi Hunter      

    /s/ David V. Smith

       Director    April 7, 2025
    David V. Smith, M.B.A.      
    Get the next $IOBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings

    $IOBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

      Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data presented at recent congresses reinforces the potential of the company's T-Win candidates to reshape the tumor microenvironment and drive more effective anti-tumor responsesCompany recognized as one of the most innovative biotechnology companies in the world by Fast Company Company to participate in TD Cowen's 6th Annual Oncology Innovation Summit on May 27 and Jefferies Global Healthcare Conference on June 4, 2025 NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinica

      5/14/25 8:05:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

      NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on th

      4/26/25 3:05:00 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

      Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company's lead investigational t

      4/25/25 1:00:00 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ahmad Qasim Iftikhar bought $26,553 worth of shares (31,350 units at $0.85) (SEC Form 4)

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      12/26/24 8:50:34 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Zocca Mai-Britt bought $10,120 worth of shares (12,500 units at $0.81), increasing direct ownership by 33% to 49,891 units (SEC Form 4)

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      12/23/24 6:56:14 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sullivan Amy bought $8,483 worth of shares (10,250 units at $0.83), increasing direct ownership by 14% to 84,632 units (SEC Form 4)

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      12/23/24 6:53:56 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Leadership Updates

    Live Leadership Updates

    See more
    • IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

      -- Enrollment Completed Ahead of Schedule --       -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab

      1/9/25 8:05:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

      NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia

      4/15/24 8:30:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

      NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome

      4/5/24 8:30:00 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    SEC Filings

    See more
    • SEC Form 10-Q filed by IO Biotech Inc.

      10-Q - IO Biotech, Inc. (0001865494) (Filer)

      5/14/25 8:54:06 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - IO Biotech, Inc. (0001865494) (Filer)

      5/14/25 8:06:21 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement

      8-K - IO Biotech, Inc. (0001865494) (Filer)

      4/30/25 4:43:01 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on IO Biotech with a new price target

      Morgan Stanley initiated coverage of IO Biotech with a rating of Overweight and set a new price target of $21.00

      11/30/21 7:56:32 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen & Co. initiated coverage on IO Biotech

      Cowen & Co. initiated coverage of IO Biotech with a rating of Outperform

      11/30/21 7:16:27 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on IO Biotech with a new price target

      Jefferies initiated coverage of IO Biotech with a rating of Buy and set a new price target of $20.00

      11/30/21 6:57:41 AM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

      SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

      11/13/24 5:30:28 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by IO Biotech Inc.

      SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)

      9/17/24 9:01:25 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

      SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

      5/14/24 9:35:27 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Zocca Mai-Britt

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      4/4/25 4:18:15 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Sullivan Amy

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      4/4/25 4:16:20 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Smith Devin Whittemore

      4 - IO Biotech, Inc. (0001865494) (Issuer)

      4/4/25 4:13:48 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOBT
    Financials

    Live finance-specific insights

    See more
    • IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

      Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec

      3/14/23 4:11:47 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IO Biotech Announces Third Quarter Results for 2022

      Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company's global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma Oral presentation and two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 37thAnnual Meeting this week will provide an overview of the Phase 1/2 study (MM1636) with IO102-IO103 in combination with nivolumab for metastatic melanoma and discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 (ARG1) and Transforming Growth Factor Beta 1 (

      11/9/22 4:05:00 PM ET
      $IOBT
      Biotechnology: Pharmaceutical Preparations
      Health Care